Hinge Health, Inc.
NYSE:HNGE · New York Stock Exchange
-$0.24 today
Vol 2.83M · Avg 1.34M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NYSE:HNGE · Revenue to Net Income
Key Ratios
Analysis
$646.3M of revenue converted into -$510.3M of net income for the selected period. Gross margin is 80.3% and net margin is -94.2%, showing how much revenue survives after costs and taxes. EPS is $-6.62, tying the income statement back to per-share earnings.
Income Statement
Annual data · 3 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $587.9M +50.6% | $390.4M +33.4% | $292.7M | $888.0M | $1.0B | $809.6M |
| Cost of Revenue | $118.6M +32.0% | $89.8M -8.9% | $98.6M | -$1.7B | $344.8M | $725.6M |
| Gross Profit | $469.3M +56.1% | $300.6M +54.8% | $194.2M | $11.6B | $10.3B | $8.9B |
| Gross Margin | 79.8% +2.8pp | 77.0% +10.7pp | 66.3% | 26.4% | 45.5% | 9.8% |
| Research & Development | $368.1M +265.1% | $100.8M -8.4% | $110.1M | $1.2B | $378.4M | $983.2M |
| Selling, General & Admin | $639.4M +181.0% | $227.5M +6.0% | $214.6M | $811.0M | $1.4B | $620.6M |
| Operating Expenses | $1.0B +205.5% | $332.5M +2.4% | $324.7M | -$15.9B | $3.6B | $5.3B |
| Depreciation & Amortization | $5.1M +118.4% | $2.4M +10.5% | $2.1M | $419.0M | $1.2B | $374.2M |
| EBITDA | -$535.9M -2327.1% | -$22.1M +82.8% | -$128.4M | $10.0B | $12.6B | -$15.2B |
| EBITDA Margin | -91.2% -85.5pp | -5.7% +38.2pp | -43.9% | 14.3% | 10.0% | 5.6% |
| Operating Income | -$546.4M -1612.2% | -$31.9M +75.6% | -$130.5M | $9.0B | $10.6B | $12.3B |
| Operating Margin | -92.9% -84.8pp | -8.2% +36.4pp | -44.6% | 11.2% | 18.7% | 16.6% |
| Interest Income | $0 | $0 | $0 | $875.4M | $1.3B | -$1.5B |
| Interest Expense | $0 | $0 | $0 | $801.2M | $969.2M | $1.1B |
| Other Income / Expenses | $19.1M -7.5% | $20.7M -6.0% | $22.0M | $368.6M | -$1.6B | -$1.5B |
| Income Before Tax | -$527.3M -4584.3% | -$11.3M +89.6% | -$108.5M | $13.9B | -$15.6B | $3.3B |
| Pre-Tax Margin | -89.7% -86.8pp | -2.9% +34.2pp | -37.1% | 15.4% | 13.3% | 20.8% |
| Income Tax Expense | $998.0K +47.4% | $677.0K +67.2% | $405.0K | $375.6M | $666.8M | $1.3B |
| Net Income | -$528.3M -4326.9% | -$11.9M +89.0% | -$108.1M | $5.1B | $5.0B | $4.9B |
| Net Margin | -89.9% -86.8pp | -3.1% +33.9pp | -36.9% | 47.3% | 7.4% | 12.4% |
| EPS (Basic) | -$5 -3473.3% | -$0 +89.2% | -$1 | $591.2M | $1.2B | $400.8M |
| EPS (Diluted) | -$5 -3360.0% | -$0 +89.2% | -$1 | $777.4M | $620.6M | $766.2M |
| Weighted Avg Shares | $79.2M +1.5% | $78.0M +0.0% | $78.0M | $724.2M | $892.2M | $757.8M |
| Weighted Avg Shares (Diluted) | $81.7M +4.7% | $78.0M +0.0% | $78.0M | $566.0M | $319.6M | $1.2B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Oscar Health, Inc.
NYSE:OSCR
$7.30B
Immunovant, Inc.
NASDAQ:IMVT
$7.25B
Lantheus Holdings, Inc.
NASDAQ:LNTH
$6.79B
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
$5.95B
Indivior Pharmaceuticals Inc
NASDAQ:INDV
$4.77B
Akero Therapeutics, Inc.
AKRO
$4.50B
Crinetics Pharmaceuticals, Inc.
NASDAQ:CRNX
$3.77B
Viking Therapeutics, Inc.
NASDAQ:VKTX
$3.62B
Dyne Therapeutics, Inc.
NASDAQ:DYN
$3.27B
GeneDx Holdings Corp.
NASDAQ:WGS
$1.69B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does HNGE generate?
Hinge Health, Inc. (HNGE) reported $587.86M of revenue in fiscal 2025.
Is HNGE profitable?
Hinge Health, Inc. (HNGE) reported -$528,260,999.00 of net income, with a net margin of -89.9%.
Explore More
Continue the stock analysis
Jump to another research area for this company.